ea0063gp223 | Adrenal and Neuroendocrine - Clinical (1) | ECE2019
Kaftanovskaya Elena
, Ng Hooi Hooi
, Soula Mariluz
, Rivas Bryan
, Myhr Courtney
, Ho Brian
, Cervantes Briana
, Bishop Colin
, Shupe Thomas
, Wilson Kenneth
, Barnaeva Elena
, Ferrer Marc
, Southall Noel
, Marugan Juan
, Agoulnik Irina
, Agoulnik Alexander
The beneficial effects of relaxin peptide treatment have been demonstrated in animal models of liver fibrosis. However, the low stability of peptide in vivo prevents using it in chronic treatments. We have identified a series of small molecule allosteric agonists of the human relaxin receptor, RXFP1. The therapeutic effects of lead compound ML290 was tested in various models of liver fibrosis. To analyze the anti-fibrotic effects of ML290 on gene expression, we used p...